查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827433

性与生殖健康药物市场（依药物类别、作用机制、处方状态、给药途径、通路和最终用户划分）－2025-2032 年全球预测

Sexual & Reproductive Health Drugs Market by Drug Class, Mechanism Of Action, Prescription Status, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年性与生殖药物市场将成长至 1,002.6 亿美元，复合年增长率为 13.72%。

主要市场统计数据
基准年2024年 358.3亿美元
预计2025年 407.2亿美元
预测年份：2032年 1002.6亿美元
复合年增长率（%） 13.72%

对塑造性与生殖医学的当代驱动因素、临床创新和不断变化的患者期​​望的权威介绍。

性与生殖健康治疗领域正处于临床创新、不断发展的监管格局和不断变化的患者期​​望的交汇点。避孕技术的进步、爱滋病毒预防策略的扩展、生育治疗和荷尔蒙替代通讯协定正与数位医疗解决方案和不断发展的报销模式相融合，这使得策略清晰度变得愈发紧迫。为此，从製造商相关人员付款人再到医疗系统的利害关係人正在重新评估产品系列、经销伙伴和证据生成的优先事项，以符合以患者为中心的医疗路径。

同时，人口结构的变化和性行为模式的改变正在重塑不同族群的需求模式。年轻族群对使用者控制和谨慎的给药系统越来越感兴趣，而老年族群对荷尔蒙疗法和生育疗法的需求也日益增长。因此，对製剂多样性、依从性支援技术和安全监测的投资正成为维持临床相关性和竞争差异化的关键。本介绍将深入探讨变革性转变、贸易政策的影响、细分市场的细微差别、区域动态、企业策略，并为引领下一阶段市场发展的领导者提供实用建议。

技术创新、监管演变和病患行为变化如何共同重塑产品开发、取得和商业策略

性与生殖健康治疗领域正经历多重同步变革时期，这些变革正在重新定义产品价值和相关人员的参与。从植入式避孕药、长效注射剂到经皮系统，药物传递技术创新日益强调耐用性、便利性和依从性。同时，数位健康平台和远端医疗的发展使得远端处方、虚拟咨询和依从性监测成为可能，从而降低了传统的获取障碍，并催生了新的分销模式。

监管趋势也在发生变化，为了因应尚未满足的临床需求，自适应路径和加速审查机制正变得越来越普遍。这种监管灵活性鼓励在生命週期的早期阶段进行投资，并促进开发商和监管机构之间更密切的对话。此外，将真实世界证据和病患报告结果纳入监管文件，也提升了上市后监测和持续品质改进的重要性。在商业性，基于价值的合约和结果挂钩定价正变得越来越普遍，这鼓励製造商将临床终点与付款人的期望和以患者为中心的指标相结合。

最后，社会和人口因素，例如避孕自主权的增强、爱滋病预防意识的提升以及生育治疗的规范化，正在重塑需求结构。因此，能够透过灵活的分销策略和强有力的循证项目来打造临床差异化的公司将在这个不断发展的市场中占据最佳地位，获得长期的竞争力。

评估 2025 年美国关税实施对更广泛的供应链、采购和临床连续性的影响

2025年美国关税的实施对性与生殖健康治疗的供应链、筹资策略和定价结构产生了即时且连锁的影响。依赖跨国采购活性药物成分、包装组件和给药装置的製造商不得不重新考虑筹资策略，以减轻利润压力。因此，为了保护生产免受关税波动的影响并保持患者护理的连续性，一些公司加快了供应商多元化，并实现了製造地的区域化。

贸易措施也影响了经销商和付款方层面的采购决策，促使企业重新评估竞标计画和合约条款，以反映日益增加的投入成本不确定性。在某些情况下，下游相关人员推迟了非必要产品线的发布，或优先考虑国内供应链的产品，以避免转嫁关税。从临床营运的角度来看，关税促使企业对库存缓衝和紧急分销路线进行更深入的情境规划，特别是对于需要低温运输和特殊处理的注射疗法和特殊避孕药。

同时，关税加速了在岸产能投资和官民合作关係的策略讨论，以确保製造业的韧性。政策制定者采取的应对措施是与产业合作，确定需要加快授权和减免关税的关键药品和零件，製造商也加强了与供应商的双边谈判，以管理前置作业时间和不断上涨的成本。整体而言，2025年的关税环境凸显了供应链透明度、灵活采购以及与采购利害关係人积极互动的策略要务，以维护病患可及性和商业性稳定性。

深度细分智能，将药物类别、给药途径和管道的差异与临床、监管和商业优先事项相结合

理解细分的细微差别对于按药物类别、机制和获取途径处理治疗和商业的复杂性至关重要。避孕药包括植入式避孕药、注射式避孕药、子宫内避孕系统、口服避孕药和经皮吸收贴片。即使是口服避孕药，各种剂型——胶囊、粉末和片剂——也决定了遵从性和製造选择。生育药物分为 GnRH 类似物、促性腺激素分泌和促排卵剂，每种都有独特的临床剂量和监测要求。爱滋病毒预防抗逆转录病毒药物，特别是含有恩曲他滨和替诺福韦的方案，涉及与公共卫生计划相交叉的持续预防策略。荷尔蒙疗法分为雌激素和黄体素途径，可用于替代和避孕。

激素和非激素药物作用机制的划分为安全性、副作用概况和患者咨询提供信息，进而影响处方模式和安排。处方环境（非处方药与处方笺药）决定了照护现场互动、消费者教育需求和自有品牌机会。考虑给药途径（注射剂、口服、外用和经皮）进一步透过胶囊、粉末和片剂区分口服製剂，确定低温运输要求、依从性考量和设备相容性。分销管道分为医院药房、网路药房和零售药房。零售进一步分为连锁店和独立商店，突显了利润结构、促销策略和伙伴关係模式的差异。最后，最终用户细分，包括诊所、居家医疗和医院，突显了采购规则、治疗通讯协定和报销途径的差异，医院分为私立和公立。结合这些细分，相关人员可以优先考虑临床开发、优化管道策略并设计符合付款人期望和患者偏好的证据生成。

区域比较突显了全球主要市场的监管复杂性、分销实践和患者行为模式

美洲、欧洲、中东和非洲以及亚太地区的区域动态差异显着，监管环境、病患行为和分销基础设施各不相同，这些都对策略产生重大影响。在美洲，整合照护模式的普及率高，且私人支付市场成熟，这支持了差异化医疗服务的快速扩张，而公共卫生计画则推动了爱滋病预防、抗逆转录抗逆转录病毒和计划生育计画的倡议。跨境关係和多样化的支付方组合使得灵活的定价和上市计划成为必要。

欧洲、中东和非洲的监管协调工作错综复杂，采购能力也千差万别。在许多市场，集中的报销决策和强大的公共部门采购管道有利于拥有强健卫生经济证据的疗法。在亚太地区，已开发国家正在加速采用数位化依从性工具和长效疗法，而其他市场则优先考虑在地化生产、价格可负担性以及透过零售和医院网路进行可扩展分销。在所有地区，符合文化背景的患者参与和细緻的监管指导仍然是成功进入市场并持续应用的先决条件。

深入了解领先的开发商如何协调产品组合创新、製造伙伴关係和证据策略，以确保临床和商业性优势

生殖治疗领域的企业策略日益受到产品组合广度、实证敏捷性和伙伴关係关係成熟度的影响。领先的研发机构正在平衡对长效给药平台（例如植入和注射剂）的投资，以及对下一代口服和经皮製剂的投资，以满足不同患者的偏好。为了支持这些创新，各公司正在改进临床试验设计，使其具有可操作的终点，并纳入患者报告的结果指标，以促进报销讨论并展示现实世界的价值。

与受託製造厂商和专业设备製造商建立策略联盟正变得越来越普遍，以降低风险并加快复杂製剂的上市时间。在商业性，企业正在多元化其分销策略，包括直接销售管道、与线上药局的合作以及针对诊所网路的客製化计画。此外，企业正在投资上市后监测基础设施和药物安全检测能力，以保持信誉并满足不断变化的监管要求。那些兼具製造韧性、主导商业化和敏捷伙伴关係模式的企业将最有可能获得长期的临床和商业性相关性。

为高阶主管提供切实可行的建议，以加强供应链、证据产生和全通路分销，加速采用并保持访问

产业领导者应采取整合方法，将临床创新与弹性供应链和以客户为中心的分销策略相结合。优先考虑采购多元化和扩大区域生产能力，以降低关税和地缘政治风险，同时投资于品管系统和供应商关係，以维护产品完整性。在考虑供应的同时，加快证据生成项目，将真实世界结果和患者报告的指标纳入其中，以支持报销谈判，并在不同的付款方环境中展示价值。

从商业性角度来看，我们将开发一种全通路分销模式，将诊所处方与线上药局管道以及有针对性的零售伙伴关係关係相结合，以扩大非处方药的可及性，同时确保对处方笺依赖性治疗进行适当的临床监管。我们还将部署用于依从性支援、远端咨询和药物安全检测的数位化工具，以改善患者疗效并收集有意义的上市后数据。最后，我们将与公共卫生项目和付款方建立合作关係，使产品引入与人口健康优先事项保持一致，提高可及性，并为更广泛的应用创造可扩展的途径。此类合作行动将增强市场韧性，并加速临床差异化治疗方法的采用。

结合主要相关人员访谈、监管机构分析和资料三角测量的严格混合方法研究框架产生了可行的见解

支撑本分析的调查方法结合了初步定性访谈、监管指南的系统性回顾以及专有临床和商业数据集的三角检验，以确保获得可靠、多观点的洞察。初步研究包括对临床医生、供应链经理、付款人和药房主任的结构化访谈，以了解实践现状和不断变化的偏好。这些洞察与对监管趋势、核准途径和上市后监管要求的全面回顾相结合，以评估政策变化如何与临床实践相互作用。

数据三角检验交叉引用了官方监管备案文件、临床试验註册中心和分销渠道信息，以检验专题研究结果。此方法优先考虑假设的透明度和对资讯来源的严格记录。在相关情况下，我们进行了情境规划练习，以探索供应链中断或政策转变对营运的影响，并进行了敏感度分析，以检验策略建议在不同市场条件下的稳健性。此混合方法框架支持基于一线经验以及已记录的监管和临床科学得出可行的结论。

策略结论强调，需要证据完整性、供应链弹性和以病人为中心的商业化来维持成长

总而言之，性与生殖医学领域的特点是技术快速进步、监管格局不断演变以及患者需求不断变化，这些因素共同创造了机会，也带来了复杂性。长效给药系统、口服和经皮製剂的多样化以及对数位化依从性工具的日益依赖，正在重新定义治疗的价值提案。同时，由于贸易动态和监管的地区差异，需要建立有韧性的供应链和灵活应变的市场进入策略，以保障病患用药和商业性可行性。

相关人员若能投资于符合付款人需求的证据生成，建构灵活的生产和分销网络，并部署以病人为中心的商业模式，将最有可能保持成长并产生临床影响。随着市场格局的不断发展，与临床、监管和供应链合作伙伴的持续合作对于将创新转化为有意义的患者治疗效果并管理营运风险至关重要。本文提供的见解将为企业在这一重要治疗领域应对短期挑战并掌握长期机会奠定策略基础。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 透过远端医疗管道快速采用自行注射皮下避孕药
  • 非专利levonorgestrel子宫内避孕器竞争对手的扩张导致已开发市场价格下跌
  • 非荷尔蒙口服男性避孕药后期临床试验的临床进展
  • 多个地区放宽了非处方事后紧急避孕药的限制
  • 透过整合数位妊娠追踪应用程式和处方荷尔蒙疗法实现个人化剂量
  • 生物相似滤泡刺激素产品的激增正在改变不孕症治疗的成本动态
  • 注射型 PrEP 产品的需求增加，此产品可提供每月预防 HIV 感染的保护
  • 针对復发性细菌性阴道炎的新兴微生物组标靶阴道疗法
  • 政策主导利用米非司酮邮购网络扩大远端医疗堕胎服务

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 性与生殖健康药物市场（依药物类别）

  • 避孕药
    • 植入式避孕器
    • 注射避孕药
    • 子宫内避孕系统
    • 口服避孕药
      • 胶囊
      • 粉末
      • 药片
    • 经皮吸收贴片
  • 治疗勃起功能障碍
  • 生育药物
    • GnRH类似物
    • 促性腺激素分泌
    • 促排卵药物
  • HIV预防抗逆转录病毒物
    • 恩曲他滨
    • 替诺福韦
  • 荷尔蒙疗法
    • 雌激素治疗
    • 黄体素治疗

9. 性与生殖药物市场（依作用机制）

  • 荷尔蒙
  • 非荷尔蒙

第 10 章。依处方情况分類的性与生殖保健药物市场

  • OTC
  • 处方

11. 性与生殖药物市场（依给药途径）

  • 注射
  • 口服
    • 胶囊
    • 粉末
    • 药片
  • 外用
  • 经皮

第 12 章。 性与生殖保健药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局
    • 连锁药局
    • 独立药房

13. 性与生殖药物市场（依最终用户）

  • 诊所
  • 居家照护
  • 医院
    • 私立医院
    • 公立医院

14. 性与生殖保健药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章。性与生殖药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 性与生殖保健药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bayer AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Ferring BV
    • Teva Pharmaceutical Industries Limited
    • Organon & Co.
    • Gedeon Richter Plc
    • HRA Pharma SAS
    • Eli Lilly and Company
Product Code: MRR-434CCDA0523A

The Sexual & Reproductive Health Drugs Market is projected to grow by USD 100.26 billion at a CAGR of 13.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 35.83 billion
Estimated Year [2025] USD 40.72 billion
Forecast Year [2032] USD 100.26 billion
CAGR (%) 13.72%

An authoritative introduction to contemporary drivers, clinical innovations, and evolving patient expectations shaping sexual and reproductive health therapeutics

The sexual and reproductive health therapeutics landscape sits at a crossroads of clinical innovation, regulatory evolution, and shifting patient expectations. Advances in contraceptive technologies, extended HIV prevention strategies, fertility interventions, and hormone replacement protocols are converging with digital health solutions and evolving reimbursement models to create renewed urgency for strategic clarity. In response, stakeholders from manufacturers to payers and health systems are re-evaluating product portfolios, distribution partnerships, and evidence generation priorities to align with patient-centered care pathways.

At the same time, demographic shifts and changing patterns of sexual behavior are reshaping demand profiles across population segments. Younger cohorts demonstrate rising interest in user-controlled methods and discreet delivery systems, while aging populations heighten demand for hormonal therapies and fertility care. Consequently, investment in formulation diversity, adherence-support technologies, and safety monitoring is becoming central to maintaining clinical relevance and competitive differentiation. This introduction sets the stage for a deeper examination of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, company strategies, and pragmatic recommendations for leaders navigating the next phase of market evolution.

How technological innovation, regulatory evolution, and shifting patient behaviors are converging to reshape product development, access, and commercial strategies

The landscape for sexual and reproductive health therapeutics is undergoing multiple, simultaneous transformations that are redefining product value and stakeholder engagement. Technological innovations in drug delivery-ranging from implantable contraceptives and long-acting injectables to transdermal systems-are increasing the emphasis on durability, convenience, and adherence. Meanwhile, the growth of digital health platforms and telemedicine is enabling remote prescribing, virtual counseling, and adherence monitoring, thereby reducing traditional access barriers and enabling new distribution models.

Regulatory trajectories are also shifting, with adaptive pathways and accelerated review mechanisms becoming more prevalent in response to unmet clinical needs. This regulatory agility is encouraging earlier lifecycle investments and closer dialogue between developers and authorities. Additionally, the integration of real-world evidence and patient-reported outcomes into regulatory dossiers is elevating the importance of post-market surveillance and continuous quality improvement. Commercially, value-based contracting and outcomes-linked pricing are gaining traction, prompting manufacturers to align clinical endpoints with payer expectations and patient-centered measures.

Finally, social and demographic forces-such as increasing contraceptive autonomy, expanded HIV prevention awareness, and the normalization of fertility interventions-are reshaping demand composition. As a result, organizations that can combine clinical differentiation with flexible distribution strategies and robust evidence programs will be best positioned to capture long-term relevance in this evolving market.

Assessing the wide-ranging supply chain, procurement, and clinical continuity effects stemming from the United States tariffs introduced in 2025

The introduction of United States tariffs in 2025 has created immediate and cascading effects across supply chains, procurement strategies, and pricing architecture for sexual and reproductive health therapeutics. Manufacturers that rely on cross-border inputs for active pharmaceutical ingredients, packaging components, and delivery devices have had to reassess sourcing strategies to mitigate margin pressure. Consequently, several firms accelerated supplier diversification and regionalized manufacturing footprints to insulate production against tariff volatility and to maintain continuity of care for patients.

Trade measures also influenced procurement decisions at the distributor and payer levels, prompting a re-evaluation of tender timelines and contractual terms to reflect increased input cost uncertainty. In certain cases, downstream stakeholders deferred non-essential pipeline launches or prioritized products with domestic supply chains to avoid exposure to tariff pass-through. From a clinical operations perspective, the tariffs have prompted more intensive scenario planning for inventory buffers and contingency distribution routes, particularly for injectable therapies and specialty contraceptives that require cold chain or specific handling.

In parallel, the tariffs accelerated strategic conversations about onshore capacity investment and public-private partnerships to secure manufacturing resilience. Policymakers responded by engaging with industry to identify critical medicines and components warranting expedited permitting or tariff relief, while manufacturers intensified bilateral negotiations with suppliers to manage lead times and cost escalation. Overall, the tariff environment in 2025 underscored the strategic imperative of supply chain transparency, flexible sourcing, and active engagement with procurement stakeholders to preserve patient access and commercial stability.

Deep segmentation intelligence that aligns drug class nuances, administration routes, and channel distinctions to clinical, regulatory, and commercial priorities

A nuanced understanding of segmentation is essential to navigate the therapeutic and commercial complexity across drug classes, mechanisms, and access pathways. Examining drug class distinctions reveals divergent development and commercialization dynamics: contraceptives encompass implantable contraceptives, injectable contraceptives, intrauterine systems, oral contraceptives, and transdermal patches; within oral contraceptives, formulation variation across capsules, powders, and tablets shapes adherence and manufacturing choices. Fertility therapies are distinguished by GnRH analogues, gonadotropins, and ovulation inducers, each with unique clinical administration and monitoring requirements. HIV prevention antiretrovirals, notably regimens including emtricitabine and tenofovir, involve sustained prophylactic strategies that intersect with public health programming, while hormonal therapies split into estrogen and progesterone pathways that serve both replacement and contraceptive indications.

Mechanism of action segmentation between hormonal and non-hormonal agents informs safety, side-effect profiles, and patient counseling, which in turn affects prescribing patterns and formulary placement. Prescription status-differentiating over-the-counter availability from prescription-only products-shapes point-of-care interactions, consumer education needs, and private-label opportunities. Route of administration considerations, spanning injectable, oral, topical, and transdermal modes with oral forms further differentiated by capsules, powders, and tablets, determine cold chain requirements, adherence considerations, and device compatibility. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy, with retail further split into chain and independent outlets, highlights divergent margin structures, promotional strategies, and partnership models. Finally, end user segmentation including clinics, home care, and hospitals, with hospitals categorized as private and public, underscores differing procurement rules, treatment protocols, and reimbursement pathways. Taken together, these segmentation lenses allow stakeholders to prioritize clinical development, optimize channel strategies, and design evidence generation that aligns with both payer expectations and patient preferences.

Comparative regional intelligence highlighting regulatory complexity, distribution realities, and patient behavior patterns across major global markets

Regional dynamics vary markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct regulatory landscapes, patient behaviors, and distribution infrastructures that materially influence strategy. In the Americas, high adoption of integrated care models and mature private pay markets support rapid uptake of differentiated delivery systems, while public health programs drive scale for HIV prevention antiretrovirals and family planning initiatives. Cross-border trade relationships and heterogenous payer mixes require adaptable pricing and market access plans.

Europe, Middle East & Africa presents a complex mosaic of regulatory harmonization efforts alongside significant variability in procurement capabilities. In many markets, centralized reimbursement decision-making and strong public sector purchasing channels favor therapies with robust health economic evidence, whereas emerging economies within the region signal demand for cost-effective, easy-to-administer solutions. Asia-Pacific demonstrates a bifurcated picture: advanced economies accelerate adoption of digitally enabled adherence tools and long-acting therapeutics, while other markets prioritize manufacturing localization, affordability, and scalable distribution through retail and hospital networks. Across all regions, culturally informed patient engagement and nuanced regulatory navigation remain prerequisites for successful market entry and sustained uptake.

Insights into how leading developers are aligning portfolio innovation, manufacturing partnerships, and evidence strategies to secure clinical and commercial advantage

Company strategies in the sexual and reproductive health therapeutics space are increasingly defined by portfolio breadth, evidence generation agility, and partnership sophistication. Leading developers are balancing investments in long-acting delivery platforms-such as implants and injectables-with next-generation oral and transdermal formulations to appeal to diverse patient preferences. To support these innovations, firms are strengthening clinical trial design with pragmatic endpoints and incorporating patient-reported outcome measures to facilitate reimbursement discussions and to demonstrate real-world value.

Strategic alliances with contract manufacturing organizations and specialized device manufacturers are becoming more common as companies seek to de-risk complex formulation launches and to accelerate time-to-market. Commercially, firms are diversifying distribution strategies to include direct-to-consumer channels, partnerships with online pharmacies, and tailored programs for clinic networks, thereby expanding reach while preserving professional oversight where clinically required. Additionally, companies are investing in post-market surveillance infrastructure and pharmacovigilance capabilities to sustain trust and comply with evolving regulatory expectations. Those that combine manufacturing resilience, evidence-led commercialization, and nimble partnership models will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for executives to fortify supply chains, evidence generation, and omnichannel distribution to accelerate adoption and preserve access

Industry leaders should pursue an integrated approach that aligns clinical innovation with resilient supply chains and customer-centric distribution strategies. Prioritize diversification of sourcing and expansion of regional manufacturing capacity to mitigate tariff and geopolitical risks, while simultaneously investing in quality management systems and supplier relationships to preserve product integrity. Parallel to supply considerations, accelerate evidence-generation programs that incorporate real-world outcomes and patient-reported measures to support reimbursement negotiations and to demonstrate value across diverse payer environments.

From a commercial perspective, develop omnichannel distribution models that blend clinic-based prescribing with online pharmacy access and targeted retail partnerships, ensuring appropriate clinical oversight for prescription-dependent therapies while expanding convenience for over-the-counter options. Embrace digital tools for adherence support, remote counseling, and pharmacovigilance to enhance patient outcomes and to gather meaningful post-launch data. Finally, pursue collaborative engagements with public health programs and payers to align product introductions with population health priorities, thereby enhancing access and creating scalable pathways for broader uptake. These coordinated actions will strengthen market resilience and accelerate adoption of clinically differentiated therapies.

A rigorous mixed-methods research framework combining primary stakeholder interviews, regulatory analysis, and data triangulation to underpin actionable findings

The research methodology underpinning this analysis combined primary qualitative interviews, systematic review of regulatory guidance, and triangulation with proprietary clinical and commercial datasets to ensure robust, multi-perspective insights. Primary research included structured interviews with clinicians, supply chain managers, payers, and pharmacy directors to capture operational realities and evolving preferences. These insights were synthesized with a comprehensive review of regulatory trends, approval pathways, and post-market surveillance requirements to assess how policy shifts interact with clinical practice.

Data triangulation involved cross-referencing public regulatory filings, clinical trial registries, and distribution channel intelligence to validate thematic findings. The approach prioritized transparency in assumptions and rigorous documentation of source provenance. Where relevant, scenario planning exercises were employed to explore the operational implications of supply chain disruptions and policy shifts, and sensitivity analyses were conducted to test the robustness of strategic recommendations under alternative market conditions. This mixed-methods framework supports actionable conclusions that are grounded in both frontline experience and documented regulatory and clinical science.

Strategic conclusions emphasizing the need for evidence alignment, supply chain resilience, and patient-centric commercialization to sustain growth

In conclusion, the sexual and reproductive health therapeutics landscape is characterized by rapid technological progress, evolving regulatory expectations, and shifting patient demand that together create both opportunity and complexity. Long-acting delivery systems, diversified oral and transdermal formulations, and increased reliance on digital adherence tools are redefining therapeutic value propositions. Concurrently, trade dynamics and regional regulatory variation necessitate resilient supply chains and adaptive market access strategies to preserve patient access and commercial viability.

Stakeholders that invest in evidence generation aligned with payer needs, build flexible manufacturing and distribution networks, and deploy patient-centric commercial models will be best positioned to sustain growth and clinical impact. As the landscape continues to evolve, continuous engagement with clinical, regulatory, and supply chain partners will be essential to translate innovation into meaningful patient outcomes while managing operational risk. The insights presented here offer a strategic foundation for organizations seeking to navigate near-term disruptions and to capitalize on long-term opportunities within this critical therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid uptake of self-administered subcutaneous injectable contraceptives via telehealth channels
  • 5.2. Expansion of generic levonorgestrel IUD competitors driving price erosion in developed markets
  • 5.3. Clinical advancement of nonhormonal oral male contraceptives undergoing late stage human trials
  • 5.4. Regulatory loosening of over-the-counter access to emergency contraceptive pills in multiple regions
  • 5.5. Integration of digital fertility tracking apps with prescription hormonal therapies for personalized dosing
  • 5.6. Surge in biosimilar follicle-stimulating hormone products reshaping fertility treatment cost dynamics
  • 5.7. Introduction of mRNA-based therapeutic vaccines targeting HPV-related cervical lesions in clinical research
  • 5.8. Rising demand for injectable PrEP formulations offering monthly protection against HIV infection
  • 5.9. Emergence of microbiome-targeted vaginal therapies for recurrent bacterial vaginosis management
  • 5.10. Policy-driven expansion of telemedicine abortion services with mail-order mifepristone distribution networks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexual & Reproductive Health Drugs Market, by Drug Class

  • 8.1. Contraceptives
    • 8.1.1. Implantable Contraceptives
    • 8.1.2. Injectable Contraceptives
    • 8.1.3. Intrauterine System
    • 8.1.4. Oral Contraceptives
      • 8.1.4.1. Capsules
      • 8.1.4.2. Powders
      • 8.1.4.3. Tablets
    • 8.1.5. Transdermal Patches
  • 8.2. Erectile Dysfunction Treatments
  • 8.3. Fertility Drugs
    • 8.3.1. GnRH Analogues
    • 8.3.2. Gonadotropins
    • 8.3.3. Ovulation Inducers
  • 8.4. HIV Prevention Antiretrovirals
    • 8.4.1. Emtricitabine
    • 8.4.2. Tenofovir
  • 8.5. Hormonal Therapies
    • 8.5.1. Estrogen Therapy
    • 8.5.2. Progesterone Therapy

9. Sexual & Reproductive Health Drugs Market, by Mechanism Of Action

  • 9.1. Hormonal
  • 9.2. Non Hormonal

10. Sexual & Reproductive Health Drugs Market, by Prescription Status

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Sexual & Reproductive Health Drugs Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Powders
    • 11.2.3. Tablets
  • 11.3. Topical
  • 11.4. Transdermal

12. Sexual & Reproductive Health Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Sexual & Reproductive Health Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals
    • 13.3.1. Private Hospitals
    • 13.3.2. Public Hospitals

14. Sexual & Reproductive Health Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexual & Reproductive Health Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexual & Reproductive Health Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bayer AG
    • 17.3.2. Pfizer Inc.
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. AbbVie Inc.
    • 17.3.5. Ferring B.V.
    • 17.3.6. Teva Pharmaceutical Industries Limited
    • 17.3.7. Organon & Co.
    • 17.3.8. Gedeon Richter Plc
    • 17.3.9. HRA Pharma SAS
    • 17.3.10. Eli Lilly and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)

TABLE 27